Retrospective cohort study of high dose proton pump inhibitor (HD-PPI) use, labeled PPI use, or H2 receptor antagonist (H2RA) use on risk of HIP fractures and a nested case-control study of cytochrome…
Ended Awarded Last action
- Contract number
- HHSF22301009T
- Awardee
-
Harvard Pilgrim Health Care, Inc. UEI NZVVQ8GNVX65
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,451,370
Award facts
- Contract value 100% obligated
- $1,451,370.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Wellesley Hills, Wellesley, MA 02481, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,451,370 |
About this award
The federal contract award is for a retrospective cohort study and nested case-control study on the risk of hip fractures associated with high-dose proton pump inhibitor (HD-PPI) use, labeled PPI use, or H2 receptor antagonist (H2RA) use. The contract was awarded by the Food and Drug Administration (FDA) to Harvard Pilgrim Health Care Inc. Office of Sponsored Programs Division, a non-profit healthcare organization with expertise in healthcare data, epidemiology, and public health research. The contract has a ceiling value of $1,451,370.15 and is a firm fixed price delivery order. This award does not have a set-aside designation. Harvard Pilgrim Health Care has extensive experience conducting large-scale observational studies and clinical trials for federal health agencies, including multi-million dollar contracts with the FDA to maintain and enhance the Sentinel System for post-market medical product safety monitoring.
Description
Retrospective cohort study of high dose proton pump inhibitor (HD-PPI) use, labeled PPI use, or H2 receptor antagonist (H2RA) use on risk of HIP fractures and a nested case-control study of cytochrome P4502C19 pharmacogenetics
Quick answers
Who was awarded contract HHSF22301009T?
HHSF22301009T was awarded to Harvard Pilgrim Health Care, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 11, 2014.
How much is contract HHSF22301009T worth?
The government has obligated $1,451,370 on HHSF22301009T.
Is contract HHSF22301009T an order under another contract?
Yes. HHSF22301009T is a delivery order under HHSF223201000009I, an indefinite delivery contract.
Was contract HHSF22301009T competed?
The extent of competition for HHSF22301009T was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award